Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2752-2755

  Hanley, William D ^a   Wenning, Larissa A ^a   Moreau, Allison ^a   Kost, James T ^a   Mangin, Eric ^a   Shamp, Trisha ^b   Stone, Julie A ^a   Gottesdiener, Keith M ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Prism Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; TIPRANAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRONES; PYRROLIDINONES; RITONAVIR; YOUNG ADULT;

EID: 66949126977     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01486-08     Document Type: Article

References (14)

1. Anderson, M. S., T. N. Kakuda, W. Hanley, J. Miller, J. T. Kost, R. Stoltz, L. A. Wenning, J. A. Stone, R. M. Hoetelmans, J. A. Wagner, and M. Iwamoto. 2008. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob. Agents Chemother. 52:4228-4232.
2. Asante-Appiah, E., and A. M. Skalka. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52:351-369.
3. Cooper, D. A., R. T. Steigbigel, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, H. Teppler, B. Y. Nguyen, and the BENCHMRK Study Teams. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
4. Esposito, D., and R. Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
5. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, R. D. Isaacs, and the Protocol 005 Team. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
6. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
7. Iwamoto, M., K. Kassahun, M. D. Troyer, W. D. Hanley, P. Lu, A. Rhoton, A. S. Petry, K. Ghosh, E. Mangin, E. P. DeNoia, L. A. Wenning, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
8. Iwamoto, M., L. A. Wenning, A. S. Petry, T. Laethem, M. De Smet, J. T. Kost, S. A. Breidinger, E. C. Mangin, N. Azrolan, H. E. Greenberg, W. Haazen, J. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Minimal effect of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 52:4338-4343.
9. Kassahun, K., I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L. A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663.
10. King, J., and E. Acosta. 2006. Tipranavir - a novel nonpeptidic protease inhibitor of HIV. Clin. Pharmacokinet. 45:665-682.
11. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
12. Merschman, S. A., P. T. Vallano, L. A. Wenning, B. K. Matuszewski, and E. J. Woolf. 2007. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B 857:15-19.
13. Steigbigel, R. T., D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, H. Teppler, and the BENCHMRK Study Teams. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
14. Wenning, L. A., H. Hanley, J. Stone, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, N. Azrolan, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto. 2006. Effect of tipranavir + ritonavir (tpv + Rtv) on pharmacokinetics of MF-0518, abstr. A-374, p. 20. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.